Solaris Commences 2024 Drilling Program at Warintza Project

Stock Information for SELLAS Life Sciences Group Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About SELLAS Life Sciences Group Inc.

SELLAS Life Sciences Announces First Pediatric AML Patient Dosed in the Ongoing Phase 2 Trial of SLS009 r/r AML
SELLAS Life Sciences Reports First Quarter 2025 Financial Results and Provides Corporate Update
SELLAS Unveils Breakthrough Preclinical Data Highlighting Efficacy of SLS009 in TP53 Mutated AML at the 2025 AACR Conference
SELLAS to Present at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
SELLAS Announces Positive Overall Survival in Cohort 3 from the Ongoing Phase 2 Trial of SLS009 in r/r AML
SELLAS Life Sciences Reports Full Year 2024 Financial Results and Provides Corporate Update
SELLAS Announces Positive Data from Phase 2a Trial of SLS009 in Combination with Zanubrutinib in DLBCL
SELLAS Life Sciences Group Announces $25 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.